A major diagnostics name just slashed its growth outlook, yet one of the world’s biggest asset managers has only grown more confident, quietly building its stake even as the stock fell. A strategic review is reportedly underway.
Here’s whether the smart money knows something headlines don’t.
Tax Strategy (Sponsored)
Capital gains taxes can take a bigger bite out of your profits than expected.
Fortunately, some deductions may help reduce the impact — including:
Investment-related expenses
Cost basis adjustments
Certain real estate selling costs
Because rules and eligibility vary, many investors turn to fiduciary financial advisors for guidance.
Q1 Was Ugly, the Guidance Got Cut, and You Should Know That Before Anything Else
Qiagen N.V. (NYSE: QGEN) reported Q1 2026 on May 6. Revenue came in at $492 million, missing the roughly $508 million consensus.
Adjusted EPS of $0.54 matched the company’s own guidance but missed the street’s $0.55 estimate by a penny. GAAP diluted EPS fell 20% to $0.33. Free cash flow dropped 44% to $53.7 million from $95.8 million.
Management then cut full-year guidance from at least 5% CER growth to 1-2%, trimmed adjusted EPS guidance from $2.50 to $2.43, and the stock fell roughly 15%.
The culprit was QuantiFERON, normally one of Qiagen’s strongest assets. It’s a blood test for latent tuberculosis infection, and a meaningful chunk of its revenue comes from immigration-related screening.
When those volumes dropped sharply in the US and Middle East, QuantiFERON revenue fell 5% CER in a single quarter.
The rest of the business didn’t fall apart: growth pillars combined were up 4% CER, and sample technologies grew 9%. One product line tied to a policy decision nobody could control dragged the whole guide lower.
Q1 revenue missed consensus by roughly $16 million: Not catastrophic, but not close either.
Full-year guidance cut from at least 5% to 1-2% CER growth: That’s not a trim. That’s a revision.
QuantiFERON fell 5% CER on immigration demand collapse: Policy-driven and theoretically reversible.
Free cash flow fell 44% to $53.7 million: Down from $95.8 million a year ago.
Management’s recovery bridge calls for roughly 4% CER growth in the second half of 2026, built from the roll-off of discontinued-platform headwinds, new product launches, easier QuantiFERON comparisons, and Parse Biosciences tracking ahead of plan.
Q2 guidance still calls for a further 2% CER decline first. This is a story you have to believe before it’s confirmed.
Action: Don’t buy this as a growth trade; size it small as speculative M&A optionality.
If Q2 (expected around August 4) comes in below the guided 2% decline, or QuantiFERON doesn’t improve sequentially, reduce.
Clean Energy (Sponsored)
The U.S. quietly labeled silver a “Critical Mineral”—but most investors haven’t noticed.
Behind the scenes, demand is rising across technology, energy, and defense… while global supply continues to tighten.
This imbalance is already pushing prices higher—and some analysts believe it’s only the beginning.
A new FREE report from Anchor Point Research breaks down what’s happening and how investors are positioning ahead of a potential surge.
BlackRock Has Spent Five Months Building a Stake, and Kept Adding After the Cut
Starting in late January 2026, BlackRock filed a series of substantial shareholding notifications disclosing a growing position in Qiagen, moving from roughly 10.3% of capital interest up through a 10.5%-11.0% range across February and March.
Here’s the detail that actually matters: the stake kept climbing after the guidance cut and the stock’s roughly 15% drop.
The most recent filing, dated May 23, 2026, shows BlackRock at approximately 11.52% of capital interest and 12.89% of voting rights, built through ordinary shares and contracts for difference.
When guidance gets cut in half and the stock falls, the normal institutional response is to reconsider. BlackRock didn’t just hold through it: the filings show it kept adding.
A firm of that scale doesn’t accidentally accumulate an 11%+ stake in a mid-cap diagnostics name during a window stacked with takeover chatter, a CEO transition, and a guidance cut.
Roughly 11.52% capital interest, 12.89% voting rights as of May 23, 2026: A concentrated, still-growing position.
Built across filings from late January through May 2026: Sustained accumulation, not index noise.
Stake increased, not decreased, after the guidance cut: Opposite of a holder reconsidering the thesis.
CFDs included throughout: Active positioning, not passive flow.
The read is straightforward: BlackRock isn’t betting that immigration volumes recover by Q3. It’s betting on a reported strategic review, and a growing double-digit stake at a deal table is a meaningful position.
Action: Track new BlackRock AFM filings. A pullback meaningfully below 10% signals weakening conviction; continued accumulation above 11.5% confirms it.
Income Strategy (Sponsored)
His official paycheck? $400,000 a year.
But the real story is somewhere else: As much as $250,000 per month… from a single source.
It’s not real estate. It’s not the stock market.
So what’s actually producing this level of cash flow — and why are more investors turning to it today?
The Strategic Review Is Real, but It Started as Press Reporting, Not a Board Mandate
Here’s the precise version: in January 2026, Bloomberg reported Qiagen was working with advisers and fielding early interest from several potential buyers, including U.S. strategics, with the company declining to comment.
The timing wasn’t random: Qiagen had disclosed in November 2025 that CEO Thierry Bernard would step down once a successor was found, a transition widely read as removing a prior deal obstacle.
Qiagen has since acknowledged on an earnings call that Moelis and Goldman Sachs are advising a strategic review, though it hasn’t issued a press release formally laying out discrete options like sale versus spinoff versus capital return.
Treat this as a real, advisor-led process the company has acknowledged, not a board mandate with a defined menu.
Thermo Fisher attempted to acquire Qiagen in 2020 at roughly $11.5-12 billion before that deal collapsed amid activist opposition; most analysts see it as a less likely repeat bidder.
The names that have actually surfaced are Agilent Technologies and Danaher. On June 25, 2026, days before this writing, diagnostics peer Bio-Techne agreed to be acquired by Merck KGaA for $73 per share, worth roughly $11.5 billion.
That’s a live, current-quarter example of a strategic buyer paying up for a life-sciences-tools platform, and exactly the kind of comp that gets cited in a review like this one.
Strategic review confirmed by CEO commentary, advised by Moelis and Goldman Sachs: Real, even without a formal press release.
CEO transition already underway: Removes a commonly cited deal obstacle.
Agilent and Danaher are the names that have surfaced as buyers: Thermo Fisher is seen as a less likely repeat bidder; Roche is reportedly entering TB testing as a QuantiFERON competitor, not a suitor.
Bio-Techne/Merck KGaA deal at $73/share, announced June 25, 2026: A live precedent in this exact sector, happening right now.
The tail risk is the same as in any unconfirmed review: talks stay preliminary and nothing formal ever launches. As of this writing, there’s no confirmed deal or formal process for Qiagen itself.
Action: On the Q2 call, listen for any move from “exploring” to a confirmed process or named timeline: that’s the signal to add. Silence means you wait.
There Is a Business Under the Immigration Testing Shock
Strip out the QuantiFERON immigration problem, and the rest of Qiagen’s portfolio isn’t falling apart. QIAstat-Dx grew sales 4% in Q1 with continued instrument placements and the kind of recurring consumable pull-through that compounds quarter after quarter.
QIAcuity digital PCR delivered double-digit CER growth on higher consumables and instrument sales, gaining traction in pharma and biotech R&D where its precision is hard to replicate.
QuantiFERON itself has two layers worth separating: the immigration-related demand that collapsed is volatile and policy-driven, while the underlying clinical latent-TB testing opportunity looks more stable.
Management still guides full-year QuantiFERON sales roughly flat versus 2025’s $503 million even with the immigration hit.
Growth pillars grew 4% CER in Q1 despite the headline miss: The immigration problem is specific, not a business-wide failure.
Sample technologies up 9% CER: The largest segment held up well.
QIAstat-Dx and QIAcuity are both growing with recurring revenue: A model that compounds.
QuantiFERON full-year sales guided roughly flat versus 2025: The immigration piece is noise on a steadier base.
Action: Watch Q2 QuantiFERON against Q1’s 5% CER decline. Improvement supports the trough thesis; further deterioration undermines the H2 bridge.
The Valuation Has Actually Gotten Cheaper, Not More Expensive
This is the section where the numbers move most, so precision matters. QGEN hit a 52-week low of $32.53 after the cut and has only recovered to roughly $38-39 as of late June 2026, nowhere near the $47-52 levels some earlier coverage assumed.
Against the floor guidance of at least $2.43 in adjusted EPS, that’s a forward multiple of roughly 15-16 times, not the ~20x figure cited off stale pricing.
Peer comparisons don’t support an “expensive” framing either. Bio-Rad trades around 33-34 times forward earnings, well above Qiagen, not below it.
Revvity trades roughly in line with or modestly above Qiagen’s multiple. And Bio-Techne, formerly a high-20s comp, is no longer a standalone comp at all; it just got acquired outright by Merck KGaA at a premium.
If anything, Qiagen screens cheap relative to comparable diagnostics names right now.
Forward PE around 15-16x at today’s ~$38 price: Modest, not expensive, for a profitable diagnostics platform.
Bio-Rad trades at a meaningfully higher multiple (~33-34x): Undercuts the “priced for perfection” framing.
Bio-Techne just got acquired at $73/share: A current precedent for premium take-outs in this sector.
35% premium on the $32.53 trough implies ~$44; on today’s ~$38 price, ~$51: More conservative than math anchored to a stale $45-48 base.
What you’re actually paying for is still the strategic review optionality, not the organic growth story, but the entry price is considerably better today than when the stock traded in the high-$40s on takeover rumors back in January.
Action: Re-run this comparison each earnings cycle.
A persistent gap between Qiagen’s mid-teens multiple and richer peers is itself part of the case for a transaction, or for a re-rating even without one.
Trivia: Buffett calls this his worst investment ever — not for the direct loss, but because of what he used to pay for it. What was it?
The Risk That Ends the Trade Is a Board That Walks Away From a Deal
A reported review that quietly fades, with no formal process and no transaction, turns this into a value trap, with the stock re-rating toward a standalone multiple that isn’t obviously above where it sits today.
The second live risk is QuantiFERON missing its H2 bridge: if immigration volumes stay suppressed, the ~4% CER growth management has guided to becomes much harder to hit, and another cut likely follows.
Two cuts in one year with no review resolution requires rethinking the whole thesis, not just resizing it.
No formal sale process ever materializing: The stock could re-rate toward a standalone multiple that isn’t above current levels.
QuantiFERON’s H2 recovery depends on immigration policy management that can’t control: A trackable risk each quarter.
A second guidance cut with no deal resolution resets the thesis: Not a recover-and-hold scenario.
FX and tariff headwinds: Background noise on top of both risks above.
Action: If subsequent quarters pass with no update on the review’s status, treat that silence as a negative signal regardless of price, and reassess position size.
Final Word: The Business Disappointed, the Bet Is on What Comes Next
Qiagen cut full-year guidance from at least 5% to 1-2%, missed Q1 estimates, and saw free cash flow drop 44%. BlackRock nonetheless kept adding, now disclosed at nearly 11.5% of capital interest.
A CEO transition is underway, the company has acknowledged an advisor-led strategic review, and peer Bio-Techne just agreed to a premium take-out by Merck KGaA, proof that strategic buyers are paying up in this space right now.
This is not a growth trade. It’s a speculative bet on a transaction outcome, alongside an institutional anchor buying through the bad news.
Small position around today’s $38-39 price, hard stop below the $32.53 post-cut low. The review’s progress on each call is the catalyst that matters most.
Setup Scorecard
Entry Window: Roughly $36-40, reflecting current pricing, well off the $32.53 low and well below January’s takeover-speculation highs.
Catalyst Watch: Strategic review update on the Q2 call (~August 4), Q2 QuantiFERON trend versus Q1’s 5% CER decline, continued BlackRock filings.
Upside Setup: A confirmed sale at a 30-40% premium, with Agilent or Danaher the more credible buyers. A 35% premium on today’s ~$38 base implies roughly $51.
Downside Cushion: BlackRock’s ~11.5% and growing anchor, the CEO transition underway, a $0.35 dividend approved at the June 24 AGM, and a now-modest ~15-16x forward multiple versus richer peers.
What Moves It Next: Confirmation (or not) of a formal review process, Q2 QuantiFERON results, further BlackRock filings, and whether the H2 bridge to ~4% CER growth shows up in Q2 commentary.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
